User:Arm7wb
| This user is a student editor in Wikipedia:Wiki_Ed/University_of_Missouri/Human_Inherited_Diseases_(Fall). Student assignments should always be carried out using a course page set up by the instructor. It is usually best to develop assignments in your sandbox. After evaluation, the additions may go on to become a Wikipedia article or be published in an existing article. |
Mutated Conditions:
Li-Fraumeni Syndrome demonstrates both allelic and locus heterogeneity, meaning that different mutations both in different genes as well as at the same locus can produce similar phenotypes. Amino acid changes (missense mutations) in the DNA binding region of p53 are more commonly associated with brain malignancies where missense mutations elsewhere in the p53 tetramer are associated with adrenocortical carcinomas [1]. Mutations that occur outside of the DNA binding domain of p53 result in a milder phenotype, and are also associated with a later age of onset for tumor development.[2] Evidence for this phenomenon suggests that mutations outside of the DNA binding region disrupt p53’s transactivation properties. Transactivation refers to a protein’s action on other genes’ behavior. p53 complexes with mutated DNA which signals for the expression and localization of other proteins that function to fix the DNA site or initiate apoptosis. Mutations that interfere with the DNA binding domain, appear to cause a more serious phenotype by disrupting the transactivation properties of the p53 protein. Cite error: There are <ref> tags on this page without content in them (see the help page).
Mes455 (talk) 04:00, 21 November 2016 (UTC)mes455
From: "Normal Conditions"
"The repair of "bad" DNA, or the apoptosis of a cell, prevents the proliferation of damaged cells." [3] Mes455 (talk) 05:29, 21 November 2016 (UTC)mes455
LFS-2
CHEK1 and CHEK2 are both required to prevent cancer malignancy. [4] In LFS-2, truncations or missense mutations in CHEK2 have resulted in a loss-of-function in which p53 is not phosphorylated by CHEK2 in response to DNA damage/cellular stress.[5] In the reported cases where CHEK2 is mutated, p53 is not mutated in the resulting tumors.[6] Mes455 (talk) 05:49, 21 November 2016 (UTC)mes455
- ^ Palmero, E., et al. 2010. “Tumor Protein 53 Mutations and Inherited Cancer: Beyond Li-Fraumeni Syndrome”. Current Opinion in Oncology. 22:64-69.
- ^ Palmero, E., et al. 2010. “Tumor Protein 53 Mutations and Inherited Cancer: Beyond Li-Fraumeni Syndrome”. Current Opinion in Oncology. 22:64-69.
- ^ Hamzehloie, T. 2012. "The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2-P53 Interaction for Cancer Therapy". IJMS. 37:3-8
- ^ Hamzehloie, T. 2012. "The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2-P53 Interaction for Cancer Therapy". IJMS. 37:3-8
- ^ Hamzehloie, T. 2012. "The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2-P53 Interaction for Cancer Therapy". IJMS. 37:3-8
- ^ Hamzehloie, T. 2012. "The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2-P53 Interaction for Cancer Therapy". IJMS. 37:3-8